$SN

Barrocas Mark sold $14.0M of SN

Barrocas Mark (Chief Executive Officer) sold 100,000 shares of SharkNinja, Inc. (SN) at $140.00 ($14.00M total) on 2026-06-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Barrocas Mark
Published Jun 23, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 23, 2026, 8:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SN
Neutral
medium confidence
Mentioned
$SN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNNeutralLow
01

Why it matters

A $14.0M open-market sale by the CEO can influence short-term sentiment, but the 10b5-1 designation suggests the trades were planned in advance.

02

Market read

Traders may monitor SN for any follow-on insider activity, but this filing alone is unlikely to drive a major repricing.

03

What to watch

Traders should check whether other insiders also sold/bought around the same window and whether the company has concurrent catalysts (earnings, guidance, product news) not mentioned here.

Relevance 6/10Novelty 6/10Timing: Filed after-hours on 2026-06-23; reflects sale executed 2026-06-18.

Background

The filing is an SEC Form 4 insider transaction for SharkNinja, Inc. (SN) by CEO Mark Barrocas.

Company-level read

Ticker impact

$SNNeutralMedium confidence
Context

SharkNinja CEO Mark Barrocas sold 100,000 shares in an open-market transaction worth $14.0M under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any effect is likely sentiment-driven and limited given the stated 10b5-1 plan.

Evidence & confidence

Form 4 discloses the sale size and that it was pre-arranged via Rule 10b5-1, reducing the signal of new negative information.

Market effects

Minimal; insider-sale disclosures rarely reset sector expectations without accompanying operational/regulatory news.

None indicated.

None indicated.

Counterpoint

Because the sale was under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.

Key entities

  • SharkNinja, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Mark Barrocas

    CEO and director who sold 100,000 shares.

  • Rule 10b5-1 plan

    Indicates the sale was pre-arranged, lowering informational content.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SNHighAI 8/10

Smith & Nephew merger talks with J&J orthopaedics unit collapse over CEO role, FT reports

Smith & Nephew's merger talks with Johnson & Johnson's orthopaedics unit collapsed over disagreement on the CEO role, according to the Financial Times. The deal would have valued the unit at up to $22 billion, nearly double Smith & Nephew's market cap. Both companies were aligned on financial terms but disagreed on leadership. Smith & Nephew's former CEO left in 2019 over pay demands.

$SNMed

UBS sees attractive risk/reward in three European medtech into Q3 results

UBS identifies Convatec, Smith & Nephew, and Sonova as attractive European medtech stocks ahead of Q3 results, citing revenue and earnings growth expectations. Convatec is expected to report 6% organic growth, Smith & Nephew may undergo a strategic review, and Sonova could raise guidance due to market growth and currency tailwinds. UBS provides price targets for each company.

$SNHighAI 8/10

Blowout Guidance Sends SharkNinja Shares Higher

SharkNinja (SN) reported Q2 2026 net sales of $1.77B (up 22.2% YoY) and adjusted net income of $178M (up 29%). The company raised full-year 2026 guidance, targeting up to 17% sales growth and $6.55 adjusted EPS. SN shares have risen 56% YTD, supported by institutional demand and strong fundamentals, including 3-year sales growth of 20% and EPS growth of 63.8%.

$SNMed

UBS raises SharkNinja stock price target to $219 on product expansion

UBS raised its price target for SharkNinja (NYSE:SN) to $219.10 from $147 and kept a Buy rating, citing Q2 results and faster product launches. The firm pointed to 13 new products year to date versus nine in the first eight months of 2025, plus plans for up to three new subcategories in 2026. SN trades at $187.68 and reported revenue of $1.77B (+22.2%) with adjusted EPS of $0.92.